The DOI matches its Crossref record; 13 of the 23 references it cites were found in a registry or an index, and 10 are not checked yet; none of the 18 sources its claims cite is checked for support yet.
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR T790M. We studied whether noninvasive genotyping of cell-free plasma DNA (cfDNA) is a useful biomarker for prediction of outcome from a third-generation EGFR-TKI, osimertinib. Methods: Plasma was collected from all patients in the first-in-man study of osimertinib. Patients who were included had acquired EGFR-TKI resistance and evidence of a common EGFR-sensitizing mutation. Genotyping of cell-free plasma DNA was performed by using BEAMing. Plasma genotyping accuracy was assessed by using tumor genotyping from a central laboratory as reference. Objective response rate (ORR) and progression-free survival (PFS) were analyzed in all T790M-positive or T790M-negative patients. Results: Sensitivity of plasma genotyping for detection of T790M was 70%. Of 58 patients with T790M-negative tumors, T790M was detected in plasma of 18 (31%). ORR and median PFS were similar in patients with T790M-positive plasma (ORR, 63%; PFS, 9.7 months) or T790M-positive tumor (ORR, 62%; PFS, 9.7 months) results. Although patients with T790M-negative plasma had overall favorable outcomes (ORR, 46%; median PFS, 8.2 months), tumor genotyping distinguished a subset of patients positive for T790M who had better outcomes (ORR, 69%; PFS, 16.5 months) as well as a subset of patients negative for T790M with poor outcomes (ORR, 25%; PFS, 2.8 months). Conclusion: In this retrospective analysis, patients positive for T790M in plasma have outcomes with osimertinib that are equivalent to patients positive by a tissue-based assay. This study suggests that, upon availability of validated plasma T790M assays, some patients could avoid a tumor biopsy for T790M genotyping. As a result of the 30% false-negative rate of plasma genotyping, those with T790M-negative plasma results still need a tumor biopsy to determine presence or absence of T790M.
Checked 2026-10-06 · 10 references not checked yet
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a retrospective analysis of the phase I AURA trial, patients with T790M detected in plasma by BEAMing had osimertinib outcomes similar to those with T790M detected in tumor tissue. Because plasma genotyping had a 30% false-negative rate for T790M, patients with T790M-negative plasma still needed tumor biopsy to determine T790M status.
Key findings
- Plasma genotyping sensitivity was 70% for T790M (111 of 158; 95% CI, 63% to 77%), 82% for exon 19 deletion (112 of 136; 95% CI, 75% to 88%), and 86% for L858R (63 of 73; 95% CI, 76% to 93%).
- Of 58 patients with T790M-negative tumors, T790M was detected in plasma in 18 (31%); repeat testing with an alternative plasma assay confirmed T790M in 14 of 18 (78%).
- ORR and median PFS were similar for T790M-positive plasma (ORR, 63%; PFS, 9.7 months) and T790M-positive tumor (ORR, 62%; PFS, 9.7 months).
- Among patients with T790M-negative plasma, tumor genotyping distinguished T790M-positive tumors (ORR, 69%; PFS, 16.5 months) from T790M-negative tumors (ORR, 25%; PFS, 2.8 months).
Methods
- Post hoc/exploratory analysis of the phase I AURA study of osimertinib in advanced EGFR-mutant NSCLC; 402 patients enrolled, 60 first-line patients excluded, 34 without a common EGFR-sensitizing mutation excluded, leaving 308 patients.
- Plasma cfDNA was collected before osimertinib and genotyped by BEAMing for T790M, L858R, and exon 19 deletion variants; positivity thresholds were ≥ 0.04% allelic fraction for exon 19 deletion or L858R and ≥ 0.06% for T790M; discordant plasma/tumor T790M results were retested with cobas plasma EGFR assay or ddPCR.
- Outcomes included confirmed ORR, maximum change in target lesion size, and PFS by RECIST version 1.1 per investigator; analyses used Clopper-Pearson exact CIs, Fisher’s exact or χ2 tests, and Kaplan-Meier estimates with log-rank tests.
Limitations
- The paper states the analysis was not preplanned, the study population was not fully representative of all acquired EGFR-TKI resistance because of intentional enrichment for T790M-positive patients, BEAMing was not performed under Clinical Laboratory Improvement Amendments conditions, and prospective validation is needed.
- Evident from the text: this was a retrospective post hoc analysis, and some key subgroups were small, such as the 18 patients with T790M-positive plasma but T790M-negative tumor genotyping.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 18 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“T790M was detected in 80% of patients (110 of 137) with versus only 5% of patients (1 of 21) without a detectable EGFR-sensitizing mutation in plasma (P<.001, Fig A2B)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Plasma genotyping resulted in rare false positives for exon 19 deletions and L858R (specificity, 98% and 97%, respectively; Table 1, Appendix Fig A2C, online only)”
Strength:plain· not yet calibratedn = 148Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“sensitivity of plasma genotyping for the known sensitizing mutation was 82% for exon 19 deletions (112 of 136; 95% CI, 75% to 88%)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“sensitivity of plasma genotyping for EGFR-sensitizing mutations was significantly higher in patients with liver metastases (94% v 79%; P = .008)”
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of 102 patients from this study with T790M-negative plasma, 45 had tumor genotyping that was positive for T790M, and these patients had a median PFS of 16.2 months, whereas 40 patients had tumor genotyping that was negative for T790M and a median PFS of 2.8 months.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and median PFS was 4.4 months (95% CI, 2.8 to 6.8 months; Appendix Fig A3, online only).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In 69 patients with TKI-sensitive EGFR mutation detected in plasma (T790M negative/sens positive), ORR was 38% (26 of 69; 95% CI, 26% to 50%)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of 58 patients with T790M-negative tumors, T790M was detected in plasma of 18 (31%).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“T790M positivity was confirmed by using an alternative assay in 14 of 18 tested plasmas (78%)”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of 102 patients from this study with T790M-negative plasma, 45 had tumor genotyping that was positive for T790M, and these patients had a median PFS of 16.2 months, whereas 40 patients had tumor genotyping that was negative for T790M and a median PFS of 2.8 months.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 21
- Probably not a substantial claim. 8
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“If plasma genotype is positive for T790M, this may obviate the need for a biopsy—this predicts for excellent outcomes on osimertinib (ORR, 63%; median PFS, 9.7 months), similar to that observed when treating with osimertinib on the basis of tumor genotyping results (ORR, 62%; median PFS, 9.7 months).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“If plasma genotype is positive for T790M, this may obviate the need for a biopsy—this predicts for excellent outcomes on osimertinib (ORR, 63%; median PFS, 9.7 months), similar to that observed when treating with osimertinib on the basis of tumor genotyping results (ORR, 62%; median PFS, 9.7 months).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median PFS was not significantly lower in those with T790M-negative plasma genotyping (8.2 months; 95% CI, 5.3 to 10.9 months; P = .188; Fig 3B).”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, in 33 patients with no EGFR mutations detected (T790M negative/sens negative), ORR was higher at 64% (21 of 33; 95% CI, 45% to 79%; P = .019)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a 9.7-month median PFS (95% CI, 8.3 to 11.1 months; Fig 3B), which is similar to outcomes in patients positive for T790M on tumor biopsy.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ORR was surprisingly high at 46% (47 of 102; 95% CI, 36% to 56%) in patients with T790M-negative plasma genotyping; however, this was still lower than in patients with T790M-positive plasma (P = .011; Fig 2D)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and median PFS was longer at 15.2 months (95% CI, 11.0 to 17.9 months; P = .002; Appendix Fig A3)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ORR was 62% (108 of 173; 95% CI, 54% to 70%) in patients with T790M-positive tumors, higher than the 26% ORR (15 of 58; 95% CI, 15% to 39%; P < .001) in patients with T790M-negative tumors”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In patients with T790M-negative/sens-positive plasma genotyping, ORR to osimertinib was 38% and median PFS was 4.4 months.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of 164 patients from this study with T790M-positive plasma genotyping, 18 had T790M-negative tumor genotyping, presumably as a result of heterogeneous presence of resistance mutation as a minor clone, and these patients had a response rate of 28% (5 of 18) and median PFS of 4.2 months.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In patients with T790M-negative/sens-negative plasma results, high ORR and prolonged PFS was observed.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Standard of care is rapidly changing with the development of third-generation, mutant-selective EGFR-TKIs that have activity against cells that harbor TKI-sensitive EGFR mutations. Unlike conventional EGFR-TKIs, this activity is maintained in the presence of T790M resistance mutation.8,9”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our data suggest that plasma and tumor genotyping can have complementary roles for T790M testing, where plasma genotyping could be the initial step and a biopsy for tumor genotyping could be supplementary (Fig 5B).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This represents a clinical challenge because tumor genotyping for EGFR T790M requires a biopsy to be performed after resistance develops, which is a procedure that carries risks, can delay subsequent therapy, and may not always be feasible.18”
What the sources say
- Not checked yetcites [18] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“At least five third-generation EGFR-TKIs are in clinical development (rociletinib, osimertinib, HM61713/BI1482694, ASP8273, and EGF816) and all have reported objective response rates (ORRs) that exceed 45% in patients with EGFR-mutant NSCLC and T790M-positive resistance.12-16”
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“which suggests that heterogeneous presence of resistance mutations across disease sites, and not false-positives of the BEAMing assay, account for the majority of T790M tissue–plasma discordance.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Noninvasive genotyping of cell-free plasma DNA (cfDNA) represents an attractive alternative for detection of EGFR T790M, noting that plasma genotyping for EGFR-sensitizing mutations is an established alternative in Europe when tumor genotyping is not feasible.19”
What the sources say
- Not checked yetcites [19] source
Strength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Resistance to conventional EGFR-TKIs develops after a median of 10 to 12 months and is most commonly mediated by an acquired mutation, T790M1-5.”
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Given the ease and reduced risk of plasma analysis compared with an invasive biopsy procedure, data support a new paradigm for resistance management, with rapid plasma genotyping as a diagnostic option before undergoing a tumor biopsy.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas it is a large analysis of a prospective dataset, it was not a preplanned analysis, in part because of the rapid evolution of plasma genotyping technologies.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite this discordance, outcomes in patients with T790M-positive plasma are similar to outcomes of patients with T790M-positive tumors, which highlights that a single tumor biopsy may not be representative of the spatial heterogeneity of resistant lung cancer.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Resistant cancers are inherently more heterogeneous than treatment-naïve cancers.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Lastly, BEAMing was not performed under Clinical Laboratory Improvement Amendments conditions; this analysis used an investigational assay that is identical to the commercially available BEAMing assay.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In a setting in which it is unclear whether tumor genotyping is representative of the entirety of the disease, clinical outcome will be the best reference standard for development of a noninvasive assay.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: Resistant cancers are inherently more heterogeneous than treatment-naïve cancers.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients negative for T790M in plasma, however, should undergo a biopsy to determine T790M status because of the risks of false-negative plasma results.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As the plasma T790M-negative population is a mixture of true and false negatives, biopsy to further investigate the presence of T790M-positive tumor tissue is warranted (Fig 5B).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this example, approximately 54% of resistant patients would be T790M positive in plasma and, if treated on the basis of that result, could potentially avoid a biopsy.”
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Resistant cancers are inherently more heterogeneous than treatment-naïve cancers.
“Resistant cancers are inherently more heterogeneous than treatment-naïve cancers and, therefore, a single tumor biopsy may not be representative of the entire resistant cancer.”
The paper relies on this without support.
The BEAMing assay has negligible false positives for T790M.
“We found that 31% of patients who are negative for T790M on central tumor genotyping have detectable T790M in plasma with a BEAMing assay that otherwise has negligible false positives, though the relative AF of plasma T790M is lower in these patients than in patients with T790M-positive plasma and tumors.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Different median PFS values for the same subgroup
MinorFor patients with T790M-negative plasma but T790M-positive tumors, the Results report a median PFS of 16.5 months, while the Discussion reports 16.2 months.
“ORR was higher in patients with T790M-positive tumors (31 of 45; 69%; 95% CI, 53% to 82%) than in patients with T790M-negative tumors (10 of 40; 25%; 95% CI, 13% to 41%; P < .001), as was median PFS (16.5 months v 2.8 months; P < .001; Fig 3C).”
“Of 102 patients from this study with T790M-negative plasma, 45 had tumor genotyping that was positive for T790M, and these patients had a median PFS of 16.2 months, whereas 40 patients had tumor genotyping that was negative for T790M and a median PFS of 2.8 months.”
Response-evaluable count presented as the plasma-positive cohort size
MinorThe Results say that 164 of the 271 plasma-genotyped patients were T790M positive, but Table A1 lists 167. The 164 figure is the denominator used for ORR, not the tabulated size of the plasma-positive cohort.
“Of 271 patients with plasma genotyping, 164 were positive for T790M in plasma and displayed a 63% ORR (103 of 164; 95% CI, 55% to 70%; Fig 2C)”
“Central (plasma) T790M mutation, No. (%) Positive 167 (54.2) 129 (54.4) 167 (61.6) 129 (59.7) Negative 104 (33.8) 87 (36.7) 104 (38.4) 87 (40.3)”
Incorrect percentage for the 80 mg tumor-genotyping subgroup
MinorTable A1 reports 90 patients at 80 mg among 237 patients with central tumor genotyping. That is 38.0%, not 40.0%.
Reported 40 · recomputed 37.974684
“Osimertinib dose, No. (%) 20 mg 21 (6.8) 13 (5.5) 21 (7.7) 13 (6.0) 40 mg 52 (16.9) 43 (18.1) 52 (19.2) 43 (20.0) 80 mg 126 (40.9) 90 (40.0) 108 (39.9) 88 (40.7)”
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationCross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Self-citationAZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citationNovel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013
Oxnard, G. R., Paweletz, C. P., Kuang, Y., Mach, S. L., O'Connell, A., Messineo, M. M., Luke, J. J., Butaney, M., Kirschmeier, P., Jackman, D. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2482 · Cited by 786
Self-citationRociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665
Self-citationFinlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 851
Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48
Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review
Tomasik, B., Skrzypski, M. T., Bieńkowski, M., Dziadziuszko, R., & Jassem, J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-742 · Cited by 48
Bartels, S., Persing, S., Hasemeier, B., Schipper, E., Kreipe, H. H., & Lehmann, U. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.05.008 · Cited by 46
Mayo‐de‐las‐Casas, C., Garzón‐Ibáñez, M., Jordana‐Ariza, N., García‐Peláez, B., Balada‐Bel, A., Villatoro, S., Malapelle, U., Karachaliou, N., Troncone, G., Rosell, R., et al. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1407243 · Cited by 47
Helden, E. J. V., Angus, L., van Oordt, C. W. M. D. H., Heideman, D. A. M., Boon, E., van Es, S. C., Radema, S. A., van Herpen, C. M. L., de Groot, D. J. A., de Vries, E. G. E., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12550 · Cited by 75
Chen, X., Liu, N., Liu, L., Chen, W., Chen, N., Lin, M., Xu, J., Zhou, X., Wang, H., Zhao, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12593-9 · Cited by 47
Arshad, J., Roberts, A., Ahmed, J., Cotta, J. A., Pico, B., Kwon, D., & Trent, J. C. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00253 · Cited by 46
Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43
Molecular Testing of Lung Cancers
Shim, H. S., Choi, Y., Kim, L., Chang, S. H., Kim, W. S., Roh, M. S., Kim, T. J., Ha, S. Y., Chung, J.-H., Jang, S. J., et al. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.04.10 · Cited by 49
Cell-Free DNA in Oncology: Gearing up for Clinic
Ulrich, B. C., & Paweletz, C. P. (2017) · Annals of Laboratory Medicine · doi:10.3343/alm.2018.38.1.1 · Cited by 47
Self-citationNon-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 48
Abbou, S., Klega, K., Tsuji, J., Tanhaemami, M., Hall, D., Barkauskas, D. A., Krailo, M. D., Cibulskis, C., Nag, A., Thorner, A. R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00409 · Cited by 44
Cucchiara, F., Re, M. D., Valleggi, S., Romei, C., Petrini, I., Lucchesi, M., Crucitta, S., Rofi, E., LIPERI, A. D., Chella, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593831 · Cited by 44
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Re, M. D., Bordi, P., Rofi, E., Restante, G., Valleggi, S., Minari, R., Crucitta, S., Arrigoni, E., Chella, A., Morganti, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0238-z · Cited by 42
Wang, V. E. H., Young, L., Ali, S. M., Miller, V. A., Urisman, A., Wolfe, J., Bivona, T. G., Damato, B. E., Fogh, S. E., & Bergsland, E. K. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0054 · Cited by 45
Yagi, S., Koh, Y., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Endo, K., Nakamura, S., Higuchi, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179744 · Cited by 44
Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43
Brown, N. A., Aisner, D. L., & Oxnard, G. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_209089 · Cited by 45
Self-citationGeva, S., Rozenblum, A. B., Twito, T., Grinberg, R., Dvir, A., Soussan‐Gutman, L., Ilouze, M., Roisman, L. C., Dudnik, E., Zer, A., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.101 · Cited by 43
Liquid Biopsies in Lung Cancer
Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A. B., & Bleckmann, A. (2023) · Cancers · doi:10.3390/cancers15051430 · Cited by 42
Deans, Z. C., Butler, R., Cheetham, M. H., Dequeker, E. M. C., Fairley, J. A., Fenizia, F., Hall, J. A., Keppens, C., Normanno, N., Schuuring, E. M. D., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02571-3 · Cited by 42
Kwon, M., Ku, B. M., Olsen, S., Park, S., Lefterova, M. I., Odegaard, J. I., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4663 · Cited by 40
Iwama, E., Sakai, K., Azuma, K., Harada, D., Nosaki, K., Hotta, K., Nishio, M., Kurata, T., Fukuhara, T., Akamatsu, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13820 · Cited by 41
Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
Loong, H. H.-F., Kwan, S.-C. S., Mok, T. S. K., & Lau, Y. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0570-9 · Cited by 41
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Liao, B.-C., Griesing, S., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890286 · Cited by 40
Self-citationKim, Y., Shin, S., & Lee, K. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01761-x · Cited by 43
Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy
Liu, S., & Wang, J. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44060184 · Cited by 41
Zou, B., Lee, V. H.-F., Chen, L., Ma, L., Wang, D. D., & Yan, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-06632-y · Cited by 40
Ding, P. N., Becker, T. M., Bray, V., Chua, W., Ma, Y., Lynch, D. T., Po, J. W., Luk, A. W. S., Caixeiro, N., SOUZA, P. D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.021 · Cited by 40
Zhang, P., Wu, X., Tang, M., Nie, X., & Li, L. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13201 · Cited by 40
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 43
Malapelle, U., Ricciuti, B., Baglivo, S., Pepe, F., Pisapia, P., Anastasi, P., Tazza, M., Sidoni, A., Liberati, A. M., Bellezza, G., et al. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_18 · Cited by 44
A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer
Heppner, D. E., & Eck, M. J. (2021) · Protein Science · doi:10.1002/pro.4125 · Cited by 39
Sharma, S., Kumar, C., Kushwaha, H., Sahil, Jha, S. K., Chawla, S., Sharma, A., Midha, T., & Huddar, V. G. (2025) · Ayush journal of integrative oncology. · doi:10.4103/ajio.ajio_3_25 · Cited by 39
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39
Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
Hofman, P. M. (2017) · Cancers · doi:10.3390/cancers9110154 · Cited by 39
Hammoud, M. K., Yosef, H. K., Lechtonen, T., Aljakouch, K., Schuler, M., Alsaidi, W., Daho, I., Maghnouj, A., Hahn, S. A., El‐Mashtoly, S. F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33682-7 · Cited by 42
Kujtan, L. A., & Subramanian, J. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1596030 · Cited by 43
Mellert, H. S., Foreman, T. M., Jackson, L. P., Maar, D., Thurston, S., Koch, K., Weaver, A., Cooper, S., Dupuis, N., Sathyanarayana, U. G., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.004 · Cited by 37
Oya, Y., Yoshida, T., Kuroda, H., Shimizu, J., Horio, Y., Sakao, Y., Inaba, Y., Hida, T., & Yatabe, Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.004 · Cited by 38
Circulating tumor DNA testing in advanced non-small cell lung cancer
Moding, E. J., Diehn, M., & Wakelee, H. A. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.02.019 · Cited by 38
Auliac, J. B., Pérol, M., Planchard, D., Monnet, I., Wislez, M., Doubre, H., Guisier, F., Pichon, É., Greillier, L., Mastroïanni, B., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.037 · Cited by 38
Iwahashi, N., Sakai, K., Noguchi, T., Yahata, T., Matsukawa, H., Toujima, S., Nishio, K., & Ino, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-47030-w · Cited by 37
Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 40
Cucchiara, F., Petrini, I., Romei, C., Crucitta, S., Lucchesi, M., Valleggi, S., Scavone, C., Capuano, A., LIPERI, A. D., Chella, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105643 · Cited by 39
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
Yang, J., Yan, H., Zhang, Y.-X., Zhang, M., Ji, B., Tian, G., Guo, Y., Tang, M., Li, L., Guo, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.725938 · Cited by 37
Self-citationLiquid Biopsy: Approaches to Dynamic Genotyping in Cancer
von Bubnoff, N. C. C. (2017) · Oncology Research and Treatment · doi:10.1159/000478864 · Cited by 38
Hoyt, K. W., Urul, D. A., Ogboo, B. C., Wittlinger, F., Laufer, S., Schaefer, E., May, E. W., & Heppner, D. E. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01502 · Cited by 35
Targeting the EGFR T790M mutation in non-small-cell lung cancer
Normanno, N., Maiello, M. R., Chicchinelli, N., Iannaccone, A., Esposito, C., Cecio, R. D., D’Alessio, A., & Luca, A. D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1272582 · Cited by 37
Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada
Stockley, T. L., Souza, C. A., Cheema, P. K., Melosky, B. L., Kamel‐Reid, S., Tsao, M., Spatz, A., & Karsan, A. (2018) · Current Oncology · doi:10.3747/co.25.4044 · Cited by 37
Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung Cancer
Cabanero, M., & Tsao, M. (2018) · Current Oncology · doi:10.3747/co.25.3761 · Cited by 35
Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST)
Jilg, S., Rassner, M. P., Maier, J., Waldeck, S., Kehl, V., Follo, M., Philipp, U., Sauter, A. P., Specht, K., Mitschke, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32282 · Cited by 36
Dono, M., Luca, G. D., Lastraioli, S., Anselmi, G., Bello, M. G. D., Coco, S., Vanni, I., Grossi, F., Vigani, A., Genova, C., et al. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0082-5 · Cited by 36
Tamminga, M., de Wit, S., Schuuring, E. M. D., Timens, W., Terstappen, L. W. M. M., Hiltermann, T. J. N., & Groen, H. J. M. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.06 · Cited by 37
Liang, Z., Cheng, Y., Chen, Y., Hu, Y., Liu, W.-P., Lü, Y., Wang, J., Wang, Y., Wu, G., Ying, J., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.008 · Cited by 36
Boonstra, P. A., ter Elst, A., Tibbesma, M., Bosman, L. J., Mathijssen, R. H. J., Atrafi, F., van Coevorden, F., Steeghs, N., Farag, S., Gelderblom, H. A. J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24493 · Cited by 35
Precision oncology in non-small-cell lung cancer: opportunities and challenges
Kim, C., & Giaccone, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0008-0 · Cited by 35
Hummelink, K., Muller, M., Linders, T. C., van der Noort, V., Nederlof, P. M., Baas, P., Burgers, S. J. A., Smit, E. F., Meijer, G. A., van den Heuvel, M. M., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00016-2019 · Cited by 35
Jönsson, V. D., Blakely, C. M., Lin, L., Asthana, S., Matni, N., Olivas, V. R., Pazarentzos, E., Gubens, M. A., Bastian, B. C., Taylor, B. S., et al. (2017) · Scientific Reports · doi:10.1038/srep44206 · Cited by 36
Remón, J., García‐Campelo, R., de Álava, E., Vera, R., Rodríguez‐Peralto, J. L., Rodríguez-Lescure, Á., Bellosillo, B., Garrido, P., Rojo, F., & Álvarez-Alegret, R. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02211-x · Cited by 37
Wu, S.-G., Chiang, C., Liu, C., Wang, C.-C., Su, P., Hsia, T., Shih, J., & Chang, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01481 · Cited by 35
Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future
Komarnicki, P., Musiałkiewicz, J., Stańska, A., Maciejewski, A., Gut, P., Mastorakos, G. P., & Ruchała, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195542 · Cited by 35
Chic, N., Mayo‐de‐las‐Casas, C., & Reguart, N. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.014 · Cited by 34
Jovelet, C., Madic, J., Remón, J., Honoré, A., Girard, R., Rouleau, É., André, B., Besse, B., Droniou, M., & Lacroix, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183319 · Cited by 33
Diagnosis: Frontiers in blood testing
Sohn, E. (2017) · Nature · doi:10.1038/549s16a · Cited by 33
Vollbrecht, C., Lehmann, A., Lenze, D., & Hummel, M. (2018) · Oncotarget · doi:10.18632/oncotarget.24908 · Cited by 34
Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer
Haentschel, M., Boeckeler, M., Ehab, A., Wagner, R. J., Spengler, W., Steger, V., Bösmüller, H. C., Horger, M., Lewis, R. A., Fend, F., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.008 · Cited by 37
Horgan, D., Čufer, T., Gatto, F., Lugowska, I. A., Verbanac, D., Carvalho, Â., Lal, J. A., Kozaric, M., Toomey, S., Ivanov, H. Y., et al. (2022) · Healthcare · doi:10.3390/healthcare10091714 · Cited by 36
Liu, Y., Li, Y., Wang, X., Liu, F., Gao, P., Quinn, M. M., Li, F., Merlino, A. A., Benes, C., Liu, Q., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0567 · Cited by 33
Perdigones, N., & Murtaza, M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.003 · Cited by 33
Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients
Kageyama, S., Nihei, K., Karasawa, K., Sawada, T., Koizumi, F., Yamaguchi, S., Kato, S., Hojo, H., Motegi, A., Tsuchihara, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25053 · Cited by 33
Noguchi, T., Iwahashi, N., Sakai, K., Matsuda, K., Matsukawa, H., Toujima, S., Nishio, K., & Ino, K. (2020) · Cancers · doi:10.3390/cancers12113382 · Cited by 33
Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer
Melosky, B. L., Blais, N., Cheema, P. K., Couture, C., Juergens, R. A., Kamel‐Reid, S., Tsao, M., Wheatley‐Price, P., Xu, Z., & Ionescu, D. N. (2018) · Current Oncology · doi:10.3747/co.25.3867 · Cited by 35
Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer
Pellini, B., Szymanski, J. J., Chin, R.-I., Jones, P. A., & Chaudhuri, A. A. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.005 · Cited by 32
Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!
Durin, L., Pradines, A., Basset, C., Ulrich, B. C., Keller, L., Dongay, V., Favre, G., Mazières, J., & Guibert, N. M. (2020) · Cells · doi:10.3390/cells9112486 · Cited by 32
Zhou, C., Yuan, Z., Ma, W., Qi, L., Mahavongtrakul, A., Li, Y., Li, H., Gong, J., Fan, R. R., Li, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0671-8 · Cited by 31
Circulating Tumor DNA: A Pan-Cancer Biomarker in Solid Tumors with Prognostic and Predictive Value
Hitchen, N., Shahnam, A., & Tie, J. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-100223-090016 · Cited by 31
Sands, J. M., Li, Q., & Hornberger, J. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.014 · Cited by 31
Fassunke, J., Ihle, M. A., Lenze, D., Lehmann, A., Hummel, M., Vollbrecht, C., Penzel, R., Volckmar, A., Stenzinger, A., Endris, V., et al. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2226-8 · Cited by 31
Minari, R., Mazzaschi, G., Bordi, P., Gnetti, L., Alberti, G., Altimari, A., Gruppioni, E., Sperandi, F., Parisi, C., Guaitoli, G., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.021 · Cited by 31
Lee, Y., Clark, E. W., Milan, M. S. D., Champagne, C., Michael, K., Awad, M. M., Barbie, D. A., Cheng, M. L., Kehl, K. L., Marcoux, J. P., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00121 · Cited by 31
Self-citationdPCR application in liquid biopsies: divide and conquer
Moreno‐Manuel, A., Fariñas, S. C., Obrador‐Hevia, A., Blasco, A., Fernandez-Diaz, A. B., Sirera, R., Camps, C., & Lewintre, E. J. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1860759 · Cited by 32
Circulating DNA in EGFR-mutated lung cancer
Singh, A. P., Li, S., & Cheng, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.07.10 · Cited by 31
Complexity of Delivering Precision Medicine: Opportunities and Challenges
Davis, A. A., McKee, A. E., Kibbe, W. A., & Villaflor, V. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200279 · Cited by 33
Sorbini, M., Carradori, T., Togliatto, G., Vaisitti, T., & Deaglio, S. (2024) · Biomolecules · doi:10.3390/biom14040498 · Cited by 32
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
Bertoli, E., Carlo, E. D., Basile, D., Zara, D., Stanzione, B., Schiappacassi, M., Conte, A. D., Spina, M., & Bearz, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310803 · Cited by 34
Baglivo, S., Ludovini, V., Sidoni, A., Metro, G., Ricciuti, B., Siggillino, A., Rebonato, A., Messina, S. G., Crinò, L., & Chiari, R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.03.022 · Cited by 30
Li, Y., Xu, H., Su, S., Ye, J., Chen, J., Jin, X., Lin, Q. D., Zhang, D., Ye, C., & Chen, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183331 · Cited by 30
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
Attili, I., Karachaliou, N., Conte, P., Bonanno, L., & Rosell, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1508347 · Cited by 32
Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC
Cheng, M. L., Lau, C. J., Milan, M. S. D., Supplee, J. G., Riess, J. W., Bradbury, P. A., Jänne, P. A., Oxnard, G. R., & Paweletz, C. P. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00419 · Cited by 29
Self-citationXie, F., Zhang, Y., Mao, X., Zheng, X., Han‐Zhang, H., Ye, J., Zhao, R., Zhang, X., & Sun, J. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.002 · Cited by 30
Safety of osimertinib in EGFR -mutated non-small cell lung cancer
Mezquita, L., Varga, A., & Planchard, D. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1549222 · Cited by 31
Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers
Swiecicki, P. L., Brennan, J. R., Mierzwa, M. L., Spector, M. E., & Brenner, J. C. (2018) · The Laryngoscope · doi:10.1002/lary.27725 · Cited by 30
Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazières, J., & Calvayrac, O. (2022) · Cancers · doi:10.3390/cancers14112613 · Cited by 32
Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
Mazza, V., & Cappuzzo, F. (2017) · The Application of Clinical Genetics · doi:10.2147/tacg.s103471 · Cited by 28
Su, K., Tseng, J., Liao, K.-M., Yang, T., Chen, K., Hsu, K.-H., Yang, P., Yu, S., & Chang, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207001 · Cited by 29
Iwama, E., Sakai, K., Hidaka, N., Inoue, K., Fujii, A., Nakagaki, N., Ota, K., Toyozawa, R., Azuma, K., Nakatomi, K., et al. (2019) · Cancer · doi:10.1002/cncr.32481 · Cited by 28
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development
Pal, A., Shinde, R., Miralles, M. S., Workman, P., & Bono, J. S. D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00489-x · Cited by 28
Kolesar, J., Peh, K. H., Thomas, L., Baburaj, G., Mukherjee, N., Kantamneni, R., Lewis, S. C., Pai, A., Udupa, K., Kumar, N. A. N., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01534-8 · Cited by 32
Metadata
- Authors
- Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A.
- Affiliations
- National Taiwan University (TW)
- Geoffrey R. Oxnard, Ryan S. Alden, Cloud P. Paweletz, and Pasi A. Jänne, Dana-Farber Cancer Institute, Boston; Kenneth S. Thress and J. Carl Barrett, AstraZeneca, Waltham, MA; Rachael Lawrance and Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; and James Chih-Hsin Yang, National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2016-10-01
- Volume
- 34
- Issue
- 28
- Pages
- 3375-3382
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC5035123
- OpenAlex
- W2468983064
- Semantic Scholar
- 120643ae96c264f871673844d9f7ad68e25ce532
- Cited by
- 850
- References
- 23
- Citations by year
- 2026: 23 · 2025: 21 · 2024: 35 · 2023: 61 · 2022: 66 · 2021: 105 · 2020: 99 · 2019: 120 · 2018: 151 · 2017: 149 · 2016: 18
- FWCI
- 130.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- National Institutes of Health
- National Cancer Institute (R01CA135257, U01CA210171)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- osimertinib, T790M mutation, liquid biopsy, plasma cell-free DNA, beaming, EGFR tyrosine kinase inhibitors, non-small cell lung cancer, treatment response prediction, false negative rate, tumor biopsy, progression-free survival, objective response rate, first-in-man trial
- MeSH terms
- Acrylamides, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, DNA, Neoplasm, Genotype, Humans, Indoles, Lung Neoplasms, Piperazines, Pyrimidines, Retrospective Studies, Biomarkers, Tumor, Treatment Outcome, Disease-Free Survival, Protein Kinase Inhibitors, Kaplan-Meier Estimate, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
